Here are our introductory comments: 

Dr. Benjamin Prosser is an Associate Professor of Physiology at the University of Pennsylvania Perelman School of Medicine.  He earned his Ph.D. in Molecular Medicine from the University of Maryland School of Medicine in 2009 and started his own lab at Penn Medicine in 2014, with an initial focus on developing novel therapeutics for heart failure.  In recognition of the lab’s cardiac work, Dr. Prosser was named the Outstanding Early Career Investigator by the American Heart Association in 2017 and received the Outstanding Investigator Award by the International Society of Heart Research in 2022.  In 2018, Dr. Prosser’s daughter Lucy was born and diagnosed with STXBP1 encephalopathy, a rare, genetic neurodevelopmental disorder.  Dr. Prosser started a separate research arm in his lab focused on developing new therapies for STXBP1 and related disorders. With Dr. Beverly Davidson at Children’s Hospital of Philadelphia he has organized the ENDD (Epilepsy and Neurodevelopmental Disorders) therapeutics team, an interdisciplinary group of clinicians and scientists primarily focused on developing RNA-based therapies for STXBP1 and SYNGAP1 related disorders. 

You may also like

74 - COMBINEDBrain Biobank & Our Partnership with SRF for SYNGAP1

Terry Jo Bichell, PhD, MPH


68 - Harnessing Messenger RNA metabolism for the development of precision gene therapy - SYNGAP1

Jeff Coller, PhD

Johns Hopkins

73 - Linking SYNGAP1 with Human-Specific Mechanisms of Neuronal Development

Pierre Vanderhaeghen, MD, PhD

VIB Center for Brain & Disease Research